RU2570397C1 - Preparation "adimast" for treatment of mastitis in cows in dry period - Google Patents

Abstract

FIELD: veterinary medicine.

SUBSTANCE: preparation comprises apramycin, xanthan gum, dioxidine, glycerin, and distilled water in the following ratio of components, wt %: apramycin - 6.8; dioxidine - 1.0; xanthan gum - 0.2; glycerin - 3.0; distilled water - 89.

EFFECT: use of the claimed preparation enables to obtain high therapeutic efficacy which is ensured by the complex combination of these substances, to prevent the extension of inflammation process, and to reduce the risk of occurrence of side effects.

1 tbl, 1 ex

Description

The invention relates to veterinary medicine, in particular for the treatment of mastitis in cows in the dry period.

A known drug for the treatment of mastitis in cows in the dry period, which includes: apramycin - 5.0-10.0%; xanthan gum - 0.25-1.0%; distilled water - the rest is up to 100% (RF patent No. 2491921, publ. 09/10/2013) [1].

The disadvantages of the drug is that it:

- inactive against anaerobic microorganisms and some types of mycoplasmas (http://gigabaza.ru/doc/5338.html) [2];

- has side effects (irritation of the mucous membrane, itching) that occur in cows in case of an increase in the concentration of xanthan gum to obtain a thicker form of the drug solution (http://ru.foodchem.com/1255/) [3].

The objective of the invention is to remedy the above disadvantages.

The problem is achieved due to the fact that the known preparation containing apramycin, xanthan gum, distilled water, according to the invention additionally contains dioxidine and glycerin in the following ratio of components, mass. %: apramycin - 6.8; dioxidine - 1.0; xanthan gum - 0.2; glycerin - 3.0; distilled water - 89.

Apramycin is an antibacterial drug of the broad-spectrum aminoglycoside group. The drug has a bactericidal effect mainly against gram-negative, some gram-positive bacteria and some types of mycoplasmas. The mechanism of antibacterial action of apramycin is due to the suppression of protein synthesis of microorganisms. A unique feature of apramycin is the lack of risk of microflora resistance formation to this antibiotic, while ensuring high efficiency even in the case of multiple drug resistance of microflora.

Dioxidin is a domestic synthetic antimicrobial drug with a wide spectrum of action (in relation to staphylococci, streptococci, meningococci, gram-negative bacteria, many anaerobes, as well as actinomycetes). The effectiveness of the drug increases in the absence of oxygen due to the stimulation of the release of reactive oxygen species. In an anaerobic environment, including and in the infected body, dioxidine stimulates the formation of free radicals, especially reactive oxygen species. This mechanism serves as the basis for a number of biochemical properties of the drug, including antibacterial activity. The therapeutic efficacy is maintained on strains resistant to other antimicrobial agents. The drug is characterized by increased reaction properties, and also easily enters into redox reactions.

Thus, dioxidine provides activity against anaerobic microorganisms and some types of mycoplasmas.

Xanthan gum is a biopolymer that is able to stabilize solutions with good emulsifying properties. It forms a protective film on the surface, moisturizes the skin and does not have a harmful effect on the body.

Glycerin is an organic compound, a representative of saturated trihydric alcohols and is a colorless viscous liquid. Used to dissolve drugs, increase the viscosity of liquid preparations and protect against changes in the fermentation of liquids. In a small percentage it has a moisturizing and softening effect. It has antiseptic and preservative properties that are associated with hygroscopicity, due to which dehydration and the death of pathogenic bacteria occur.

The complex combination of these drugs apramycin, dioxidine, xanthan gum and glycerin provides increased therapeutic efficacy, the necessary density of the solution, reduced risk of side effects and safety for the treatment of mastitis in cows in the dry period.

The inventive drug was used to treat mastitis in cows in the dry period on milk farms IP Koskina II, located in the Oryol region in the Bolkhov region.

The identification of patients with mastitis in cows was carried out in accordance with the instruction “Instructions for the diagnosis, therapy and prevention of mastitis in cows” (2000). Subclinical mastitis was detected using a rapid mastitis test (BMT). Clinical mastitis was diagnosed visually by the nature of the secretion of the mammary gland.

Microbiological examination of milk revealed staphylococci, streptococci, BGKP and clostridia.

For research, four groups of cows were selected, two of which (1 and 2) (one with subclinical and the other with clinical mastitis) were treated with a well-known drug, the other two groups of cows (3-4) (with subclinical and clinical mastitis) - according to the proposed method .

The drugs were injected into all four lobes of the udder, regardless of their defeat. Groups of cows 3 and 4 were treated with the proposed drug. The drug was administered to cows intercisternally in an amount of 10 ml after the last evening milking during start-up in the dry period. In subclinical mastitis, the drug was administered once, and in clinical twice: during start-up and after 2 weeks. Before the introduction of the drug, the secret was released from the affected portion of the udder of the cow and disposed of, the nipple was disinfected. In the cold season, the preparation was heated to 37 ° C before use, and it was thoroughly shaken until a uniform suspension was obtained. From the vial, the preparation was taken into a sterile syringe 10 ml. The nipple was disinfected with an alcohol swab. The syringe was tightly pressed to the external opening of the nipple canal, the preparation was introduced into the udder nipple by carefully pressing the syringe plunger. After administration of the drug, a light massage of the nipple of the affected lobe of the udder was performed from the bottom up.

The results of treatment of cows with subclinical and clinical forms of mastitis in the dry period are shown in the table.

Based on the tests, the therapeutic efficacy of the proposed drug was established both in the subclinical and in the clinical form of mastitis in the dry period of cows, including those caused by anaerobic microorganisms.

The proposed drug did not cause side effects, in contrast to the known, which provoked an allergic reaction in 3 out of 17 cows.

The use of the proposed drug for the treatment of mastitis in cows in the dry period allows to obtain high therapeutic efficacy, which is ensured by a complex combination of these substances, and to prevent the spread of the inflammatory process.

Claims (1)

The drug for the treatment of mastitis in cows in the dry period, containing apramycin, xanthan gum and distilled water, characterized in that it additionally contains dioxidine and glycerin in the following ratio, wt. %:
Apramycin 6.8 Dioxidine 1,0 Xanthan gum 0.2 Glycerol 3.0 Distilled water 89